Analytical Data
-
Gene name
pcl
- Application
-
Alternative Names
(4CL)(4-coumaroyl-CoA synthase)
-
Species
Rhodobacter capsulatus
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O69140
-
Expression Region
1-384aa
-
Molecular Weight
47.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PCL (Polycaprolactone) is a biodegradable polyester widely studied for its potential applications in tissue engineering and drug delivery systems. The interest in PCL and its recombinant proteins has surged due to the growing demand for sustainable and biocompatible materials in biomedical applications. The ability to engineer proteins that mimic the structure or functionality of natural proteins opens up avenues for advanced therapeutic strategies. PCL-based recombinant proteins, particularly those enhancing cell adhesion and proliferation, are essential for tissue regeneration. These proteins can be combined with scaffolds made of PCL to create composite materials that provide structural support while promoting cellular activities necessary for tissue repair. Furthermore, the development of PCL-recombinant protein constructs can lead to innovative drug delivery systems that ensure controlled release and targeted delivery of therapeutic agents. The ongoing research in this field is focused on optimizing the production processes of these recombinant proteins, exploring their interactions with various cell types, and assessing their performance in in vivo models. The integration of advances in biotechnology with the versatile properties of PCL has the potential to revolutionize approaches in regenerative medicine and pharmaceuticals, thus paving the way for new treatments for a variety of conditions.
